Biomed Pharmacother:血管生成素2促进组织工程骨中的血管生成,并通过诱导自噬改善骨缺损的修复

2018-07-20 MedSci MedSci原创

血管生成在组织工程骨修复大节段性骨缺损中起关键作用。然而,目前还未有有效的方法促进组织工程骨中的血管生成。研究已经证实血管生成素2(Ang2)和自噬均与血管生成有关,但其在组织工程骨的血管生成中的作用仍然未知。 体内研究中,使用新西兰白兔制造桡骨缺损,植入羟基磷灰石/胶原支架然后注射不同浓度的Ang2来治疗。通过蛋白质印迹法测量自噬调节剂微管相关蛋白1轻链3(LC3),Beclin-1和SQ

血管生成在组织工程骨修复大节段性骨缺损中起关键作用。然而,目前还未有有效的方法促进组织工程骨中的血管生成。研究已经证实血管生成素2(Ang2)和自噬均与血管生成有关,但其在组织工程骨的血管生成中的作用仍然未知。

体内研究中,使用新西兰白兔制造桡骨缺损,植入羟基磷灰石/胶原支架然后注射不同浓度的Ang2来治疗。通过蛋白质印迹法测量自噬调节剂微管相关蛋白1轻链3(LC3),Beclin-1和SQSTM1/P62的表达,同时通过蛋白质印迹和免疫组织化学检测血管生成调节剂VEGF和CD31的表达。一般观察结合X射线成像评估骨缺损愈合。

结果显示,随着Ang2浓度的增加,LC3-I/LC3-II,Beclin-1,VEGF和CD31在骨缺损区的表达增加,SQSTM1/p62以剂量依赖性方式降低。在用高浓度Ang2处理的组中,骨组织生长良好,伴有明显的血管生成,导致骨缺损的良好修复。然而,在低浓度的Ang2组中,尽管存在血管生成和新骨形成,但骨缺损未得到修复。此外,对照组中血管生成和骨生成均受阻。

综上所述,该研究研究表明,高浓度的Ang2促进组织工程骨中的血管生成,并通过诱导自噬改善骨缺损的修复。

原始出处:

Yin J, Gong G, et al., Angiopoietin 2 promotes angiogenesis in tissue-engineered bone and improves repair of bone defects by inducing autophagy. Biomed Pharmacother. 2018 Sep;105:932-939. doi: 10.1016/j.biopha.2018.06.078. Epub 2018 Jun 19.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (21)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1918207, encodeId=50a4191820e2e, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Mar 14 07:38:00 CST 2019, time=2019-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787506, encodeId=29761e87506a3, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Thu Jul 04 02:38:00 CST 2019, time=2019-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996200, encodeId=62831996200e4, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon May 06 12:38:00 CST 2019, time=2019-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990152, encodeId=5c69199015260, content=<a href='/topic/show?id=e2ea89e07d9' target=_blank style='color:#2F92EE;'>#血管生成素2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89707, encryptionId=e2ea89e07d9, topicName=血管生成素2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Sat Dec 08 13:38:00 CST 2018, time=2018-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908450, encodeId=359a190845027, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sun Feb 10 06:38:00 CST 2019, time=2019-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666882, encodeId=d9c11666882f2, content=<a href='/topic/show?id=93bc89e043b' target=_blank style='color:#2F92EE;'>#血管生成素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89704, encryptionId=93bc89e043b, topicName=血管生成素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff2526069317, createdName=xinmeili, createdTime=Sat Dec 29 02:38:00 CST 2018, time=2018-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334060, encodeId=9f1e334060bb, content=学了, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKcmgibQ4oCrK7Z6f4CvMcs4k7QUGCkhopcGxvxaBfVciadECSIwaRVttllIOEKumpEaRrq5PoOUxow/0, createdBy=e3bb2081203, createdName=哈哈869, createdTime=Wed Jul 25 12:04:04 CST 2018, time=2018-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333718, encodeId=7788333e185a, content=学了, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKcmgibQ4oCrK7Z6f4CvMcs4k7QUGCkhopcGxvxaBfVciadECSIwaRVttllIOEKumpEaRrq5PoOUxow/0, createdBy=e3bb2081203, createdName=哈哈869, createdTime=Tue Jul 24 00:12:38 CST 2018, time=2018-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417181, encodeId=7938141e181b5, content=<a href='/topic/show?id=8b72e769056' target=_blank style='color:#2F92EE;'>#组织工程#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77690, encryptionId=8b72e769056, topicName=组织工程)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c62f3243688, createdName=zhu_jun9838, createdTime=Sun Jul 22 13:38:00 CST 2018, time=2018-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419267, encodeId=22ae141926e2f, content=<a href='/topic/show?id=2e2e10182602' target=_blank style='color:#2F92EE;'>#骨缺损#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101826, encryptionId=2e2e10182602, topicName=骨缺损)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51173492599, createdName=lfcmxl, createdTime=Sun Jul 22 13:38:00 CST 2018, time=2018-07-22, status=1, ipAttribution=)]
    2019-03-14 sunylz
  2. [GetPortalCommentsPageByObjectIdResponse(id=1918207, encodeId=50a4191820e2e, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Mar 14 07:38:00 CST 2019, time=2019-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787506, encodeId=29761e87506a3, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Thu Jul 04 02:38:00 CST 2019, time=2019-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996200, encodeId=62831996200e4, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon May 06 12:38:00 CST 2019, time=2019-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990152, encodeId=5c69199015260, content=<a href='/topic/show?id=e2ea89e07d9' target=_blank style='color:#2F92EE;'>#血管生成素2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89707, encryptionId=e2ea89e07d9, topicName=血管生成素2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Sat Dec 08 13:38:00 CST 2018, time=2018-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908450, encodeId=359a190845027, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sun Feb 10 06:38:00 CST 2019, time=2019-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666882, encodeId=d9c11666882f2, content=<a href='/topic/show?id=93bc89e043b' target=_blank style='color:#2F92EE;'>#血管生成素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89704, encryptionId=93bc89e043b, topicName=血管生成素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff2526069317, createdName=xinmeili, createdTime=Sat Dec 29 02:38:00 CST 2018, time=2018-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334060, encodeId=9f1e334060bb, content=学了, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKcmgibQ4oCrK7Z6f4CvMcs4k7QUGCkhopcGxvxaBfVciadECSIwaRVttllIOEKumpEaRrq5PoOUxow/0, createdBy=e3bb2081203, createdName=哈哈869, createdTime=Wed Jul 25 12:04:04 CST 2018, time=2018-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333718, encodeId=7788333e185a, content=学了, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKcmgibQ4oCrK7Z6f4CvMcs4k7QUGCkhopcGxvxaBfVciadECSIwaRVttllIOEKumpEaRrq5PoOUxow/0, createdBy=e3bb2081203, createdName=哈哈869, createdTime=Tue Jul 24 00:12:38 CST 2018, time=2018-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417181, encodeId=7938141e181b5, content=<a href='/topic/show?id=8b72e769056' target=_blank style='color:#2F92EE;'>#组织工程#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77690, encryptionId=8b72e769056, topicName=组织工程)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c62f3243688, createdName=zhu_jun9838, createdTime=Sun Jul 22 13:38:00 CST 2018, time=2018-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419267, encodeId=22ae141926e2f, content=<a href='/topic/show?id=2e2e10182602' target=_blank style='color:#2F92EE;'>#骨缺损#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101826, encryptionId=2e2e10182602, topicName=骨缺损)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51173492599, createdName=lfcmxl, createdTime=Sun Jul 22 13:38:00 CST 2018, time=2018-07-22, status=1, ipAttribution=)]
    2019-07-04 jj000001
  3. [GetPortalCommentsPageByObjectIdResponse(id=1918207, encodeId=50a4191820e2e, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Mar 14 07:38:00 CST 2019, time=2019-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787506, encodeId=29761e87506a3, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Thu Jul 04 02:38:00 CST 2019, time=2019-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996200, encodeId=62831996200e4, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon May 06 12:38:00 CST 2019, time=2019-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990152, encodeId=5c69199015260, content=<a href='/topic/show?id=e2ea89e07d9' target=_blank style='color:#2F92EE;'>#血管生成素2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89707, encryptionId=e2ea89e07d9, topicName=血管生成素2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Sat Dec 08 13:38:00 CST 2018, time=2018-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908450, encodeId=359a190845027, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sun Feb 10 06:38:00 CST 2019, time=2019-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666882, encodeId=d9c11666882f2, content=<a href='/topic/show?id=93bc89e043b' target=_blank style='color:#2F92EE;'>#血管生成素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89704, encryptionId=93bc89e043b, topicName=血管生成素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff2526069317, createdName=xinmeili, createdTime=Sat Dec 29 02:38:00 CST 2018, time=2018-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334060, encodeId=9f1e334060bb, content=学了, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKcmgibQ4oCrK7Z6f4CvMcs4k7QUGCkhopcGxvxaBfVciadECSIwaRVttllIOEKumpEaRrq5PoOUxow/0, createdBy=e3bb2081203, createdName=哈哈869, createdTime=Wed Jul 25 12:04:04 CST 2018, time=2018-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333718, encodeId=7788333e185a, content=学了, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKcmgibQ4oCrK7Z6f4CvMcs4k7QUGCkhopcGxvxaBfVciadECSIwaRVttllIOEKumpEaRrq5PoOUxow/0, createdBy=e3bb2081203, createdName=哈哈869, createdTime=Tue Jul 24 00:12:38 CST 2018, time=2018-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417181, encodeId=7938141e181b5, content=<a href='/topic/show?id=8b72e769056' target=_blank style='color:#2F92EE;'>#组织工程#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77690, encryptionId=8b72e769056, topicName=组织工程)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c62f3243688, createdName=zhu_jun9838, createdTime=Sun Jul 22 13:38:00 CST 2018, time=2018-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419267, encodeId=22ae141926e2f, content=<a href='/topic/show?id=2e2e10182602' target=_blank style='color:#2F92EE;'>#骨缺损#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101826, encryptionId=2e2e10182602, topicName=骨缺损)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51173492599, createdName=lfcmxl, createdTime=Sun Jul 22 13:38:00 CST 2018, time=2018-07-22, status=1, ipAttribution=)]
    2019-05-06 yb6560
  4. [GetPortalCommentsPageByObjectIdResponse(id=1918207, encodeId=50a4191820e2e, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Mar 14 07:38:00 CST 2019, time=2019-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787506, encodeId=29761e87506a3, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Thu Jul 04 02:38:00 CST 2019, time=2019-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996200, encodeId=62831996200e4, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon May 06 12:38:00 CST 2019, time=2019-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990152, encodeId=5c69199015260, content=<a href='/topic/show?id=e2ea89e07d9' target=_blank style='color:#2F92EE;'>#血管生成素2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89707, encryptionId=e2ea89e07d9, topicName=血管生成素2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Sat Dec 08 13:38:00 CST 2018, time=2018-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908450, encodeId=359a190845027, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sun Feb 10 06:38:00 CST 2019, time=2019-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666882, encodeId=d9c11666882f2, content=<a href='/topic/show?id=93bc89e043b' target=_blank style='color:#2F92EE;'>#血管生成素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89704, encryptionId=93bc89e043b, topicName=血管生成素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff2526069317, createdName=xinmeili, createdTime=Sat Dec 29 02:38:00 CST 2018, time=2018-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334060, encodeId=9f1e334060bb, content=学了, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKcmgibQ4oCrK7Z6f4CvMcs4k7QUGCkhopcGxvxaBfVciadECSIwaRVttllIOEKumpEaRrq5PoOUxow/0, createdBy=e3bb2081203, createdName=哈哈869, createdTime=Wed Jul 25 12:04:04 CST 2018, time=2018-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333718, encodeId=7788333e185a, content=学了, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKcmgibQ4oCrK7Z6f4CvMcs4k7QUGCkhopcGxvxaBfVciadECSIwaRVttllIOEKumpEaRrq5PoOUxow/0, createdBy=e3bb2081203, createdName=哈哈869, createdTime=Tue Jul 24 00:12:38 CST 2018, time=2018-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417181, encodeId=7938141e181b5, content=<a href='/topic/show?id=8b72e769056' target=_blank style='color:#2F92EE;'>#组织工程#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77690, encryptionId=8b72e769056, topicName=组织工程)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c62f3243688, createdName=zhu_jun9838, createdTime=Sun Jul 22 13:38:00 CST 2018, time=2018-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419267, encodeId=22ae141926e2f, content=<a href='/topic/show?id=2e2e10182602' target=_blank style='color:#2F92EE;'>#骨缺损#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101826, encryptionId=2e2e10182602, topicName=骨缺损)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51173492599, createdName=lfcmxl, createdTime=Sun Jul 22 13:38:00 CST 2018, time=2018-07-22, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1918207, encodeId=50a4191820e2e, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Mar 14 07:38:00 CST 2019, time=2019-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787506, encodeId=29761e87506a3, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Thu Jul 04 02:38:00 CST 2019, time=2019-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996200, encodeId=62831996200e4, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon May 06 12:38:00 CST 2019, time=2019-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990152, encodeId=5c69199015260, content=<a href='/topic/show?id=e2ea89e07d9' target=_blank style='color:#2F92EE;'>#血管生成素2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89707, encryptionId=e2ea89e07d9, topicName=血管生成素2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Sat Dec 08 13:38:00 CST 2018, time=2018-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908450, encodeId=359a190845027, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sun Feb 10 06:38:00 CST 2019, time=2019-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666882, encodeId=d9c11666882f2, content=<a href='/topic/show?id=93bc89e043b' target=_blank style='color:#2F92EE;'>#血管生成素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89704, encryptionId=93bc89e043b, topicName=血管生成素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff2526069317, createdName=xinmeili, createdTime=Sat Dec 29 02:38:00 CST 2018, time=2018-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334060, encodeId=9f1e334060bb, content=学了, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKcmgibQ4oCrK7Z6f4CvMcs4k7QUGCkhopcGxvxaBfVciadECSIwaRVttllIOEKumpEaRrq5PoOUxow/0, createdBy=e3bb2081203, createdName=哈哈869, createdTime=Wed Jul 25 12:04:04 CST 2018, time=2018-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333718, encodeId=7788333e185a, content=学了, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKcmgibQ4oCrK7Z6f4CvMcs4k7QUGCkhopcGxvxaBfVciadECSIwaRVttllIOEKumpEaRrq5PoOUxow/0, createdBy=e3bb2081203, createdName=哈哈869, createdTime=Tue Jul 24 00:12:38 CST 2018, time=2018-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417181, encodeId=7938141e181b5, content=<a href='/topic/show?id=8b72e769056' target=_blank style='color:#2F92EE;'>#组织工程#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77690, encryptionId=8b72e769056, topicName=组织工程)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c62f3243688, createdName=zhu_jun9838, createdTime=Sun Jul 22 13:38:00 CST 2018, time=2018-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419267, encodeId=22ae141926e2f, content=<a href='/topic/show?id=2e2e10182602' target=_blank style='color:#2F92EE;'>#骨缺损#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101826, encryptionId=2e2e10182602, topicName=骨缺损)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51173492599, createdName=lfcmxl, createdTime=Sun Jul 22 13:38:00 CST 2018, time=2018-07-22, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1918207, encodeId=50a4191820e2e, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Mar 14 07:38:00 CST 2019, time=2019-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787506, encodeId=29761e87506a3, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Thu Jul 04 02:38:00 CST 2019, time=2019-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996200, encodeId=62831996200e4, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon May 06 12:38:00 CST 2019, time=2019-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990152, encodeId=5c69199015260, content=<a href='/topic/show?id=e2ea89e07d9' target=_blank style='color:#2F92EE;'>#血管生成素2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89707, encryptionId=e2ea89e07d9, topicName=血管生成素2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Sat Dec 08 13:38:00 CST 2018, time=2018-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908450, encodeId=359a190845027, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sun Feb 10 06:38:00 CST 2019, time=2019-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666882, encodeId=d9c11666882f2, content=<a href='/topic/show?id=93bc89e043b' target=_blank style='color:#2F92EE;'>#血管生成素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89704, encryptionId=93bc89e043b, topicName=血管生成素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff2526069317, createdName=xinmeili, createdTime=Sat Dec 29 02:38:00 CST 2018, time=2018-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334060, encodeId=9f1e334060bb, content=学了, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKcmgibQ4oCrK7Z6f4CvMcs4k7QUGCkhopcGxvxaBfVciadECSIwaRVttllIOEKumpEaRrq5PoOUxow/0, createdBy=e3bb2081203, createdName=哈哈869, createdTime=Wed Jul 25 12:04:04 CST 2018, time=2018-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333718, encodeId=7788333e185a, content=学了, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKcmgibQ4oCrK7Z6f4CvMcs4k7QUGCkhopcGxvxaBfVciadECSIwaRVttllIOEKumpEaRrq5PoOUxow/0, createdBy=e3bb2081203, createdName=哈哈869, createdTime=Tue Jul 24 00:12:38 CST 2018, time=2018-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417181, encodeId=7938141e181b5, content=<a href='/topic/show?id=8b72e769056' target=_blank style='color:#2F92EE;'>#组织工程#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77690, encryptionId=8b72e769056, topicName=组织工程)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c62f3243688, createdName=zhu_jun9838, createdTime=Sun Jul 22 13:38:00 CST 2018, time=2018-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419267, encodeId=22ae141926e2f, content=<a href='/topic/show?id=2e2e10182602' target=_blank style='color:#2F92EE;'>#骨缺损#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101826, encryptionId=2e2e10182602, topicName=骨缺损)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51173492599, createdName=lfcmxl, createdTime=Sun Jul 22 13:38:00 CST 2018, time=2018-07-22, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1918207, encodeId=50a4191820e2e, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Mar 14 07:38:00 CST 2019, time=2019-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787506, encodeId=29761e87506a3, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Thu Jul 04 02:38:00 CST 2019, time=2019-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996200, encodeId=62831996200e4, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon May 06 12:38:00 CST 2019, time=2019-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990152, encodeId=5c69199015260, content=<a href='/topic/show?id=e2ea89e07d9' target=_blank style='color:#2F92EE;'>#血管生成素2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89707, encryptionId=e2ea89e07d9, topicName=血管生成素2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Sat Dec 08 13:38:00 CST 2018, time=2018-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908450, encodeId=359a190845027, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sun Feb 10 06:38:00 CST 2019, time=2019-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666882, encodeId=d9c11666882f2, content=<a href='/topic/show?id=93bc89e043b' target=_blank style='color:#2F92EE;'>#血管生成素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89704, encryptionId=93bc89e043b, topicName=血管生成素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff2526069317, createdName=xinmeili, createdTime=Sat Dec 29 02:38:00 CST 2018, time=2018-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334060, encodeId=9f1e334060bb, content=学了, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKcmgibQ4oCrK7Z6f4CvMcs4k7QUGCkhopcGxvxaBfVciadECSIwaRVttllIOEKumpEaRrq5PoOUxow/0, createdBy=e3bb2081203, createdName=哈哈869, createdTime=Wed Jul 25 12:04:04 CST 2018, time=2018-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333718, encodeId=7788333e185a, content=学了, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKcmgibQ4oCrK7Z6f4CvMcs4k7QUGCkhopcGxvxaBfVciadECSIwaRVttllIOEKumpEaRrq5PoOUxow/0, createdBy=e3bb2081203, createdName=哈哈869, createdTime=Tue Jul 24 00:12:38 CST 2018, time=2018-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417181, encodeId=7938141e181b5, content=<a href='/topic/show?id=8b72e769056' target=_blank style='color:#2F92EE;'>#组织工程#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77690, encryptionId=8b72e769056, topicName=组织工程)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c62f3243688, createdName=zhu_jun9838, createdTime=Sun Jul 22 13:38:00 CST 2018, time=2018-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419267, encodeId=22ae141926e2f, content=<a href='/topic/show?id=2e2e10182602' target=_blank style='color:#2F92EE;'>#骨缺损#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101826, encryptionId=2e2e10182602, topicName=骨缺损)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51173492599, createdName=lfcmxl, createdTime=Sun Jul 22 13:38:00 CST 2018, time=2018-07-22, status=1, ipAttribution=)]
    2018-07-25 哈哈869

    学了

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1918207, encodeId=50a4191820e2e, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Mar 14 07:38:00 CST 2019, time=2019-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787506, encodeId=29761e87506a3, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Thu Jul 04 02:38:00 CST 2019, time=2019-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996200, encodeId=62831996200e4, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon May 06 12:38:00 CST 2019, time=2019-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990152, encodeId=5c69199015260, content=<a href='/topic/show?id=e2ea89e07d9' target=_blank style='color:#2F92EE;'>#血管生成素2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89707, encryptionId=e2ea89e07d9, topicName=血管生成素2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Sat Dec 08 13:38:00 CST 2018, time=2018-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908450, encodeId=359a190845027, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sun Feb 10 06:38:00 CST 2019, time=2019-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666882, encodeId=d9c11666882f2, content=<a href='/topic/show?id=93bc89e043b' target=_blank style='color:#2F92EE;'>#血管生成素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89704, encryptionId=93bc89e043b, topicName=血管生成素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff2526069317, createdName=xinmeili, createdTime=Sat Dec 29 02:38:00 CST 2018, time=2018-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334060, encodeId=9f1e334060bb, content=学了, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKcmgibQ4oCrK7Z6f4CvMcs4k7QUGCkhopcGxvxaBfVciadECSIwaRVttllIOEKumpEaRrq5PoOUxow/0, createdBy=e3bb2081203, createdName=哈哈869, createdTime=Wed Jul 25 12:04:04 CST 2018, time=2018-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333718, encodeId=7788333e185a, content=学了, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKcmgibQ4oCrK7Z6f4CvMcs4k7QUGCkhopcGxvxaBfVciadECSIwaRVttllIOEKumpEaRrq5PoOUxow/0, createdBy=e3bb2081203, createdName=哈哈869, createdTime=Tue Jul 24 00:12:38 CST 2018, time=2018-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417181, encodeId=7938141e181b5, content=<a href='/topic/show?id=8b72e769056' target=_blank style='color:#2F92EE;'>#组织工程#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77690, encryptionId=8b72e769056, topicName=组织工程)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c62f3243688, createdName=zhu_jun9838, createdTime=Sun Jul 22 13:38:00 CST 2018, time=2018-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419267, encodeId=22ae141926e2f, content=<a href='/topic/show?id=2e2e10182602' target=_blank style='color:#2F92EE;'>#骨缺损#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101826, encryptionId=2e2e10182602, topicName=骨缺损)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51173492599, createdName=lfcmxl, createdTime=Sun Jul 22 13:38:00 CST 2018, time=2018-07-22, status=1, ipAttribution=)]
    2018-07-24 哈哈869

    学了

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1918207, encodeId=50a4191820e2e, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Mar 14 07:38:00 CST 2019, time=2019-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787506, encodeId=29761e87506a3, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Thu Jul 04 02:38:00 CST 2019, time=2019-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996200, encodeId=62831996200e4, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon May 06 12:38:00 CST 2019, time=2019-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990152, encodeId=5c69199015260, content=<a href='/topic/show?id=e2ea89e07d9' target=_blank style='color:#2F92EE;'>#血管生成素2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89707, encryptionId=e2ea89e07d9, topicName=血管生成素2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Sat Dec 08 13:38:00 CST 2018, time=2018-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908450, encodeId=359a190845027, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sun Feb 10 06:38:00 CST 2019, time=2019-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666882, encodeId=d9c11666882f2, content=<a href='/topic/show?id=93bc89e043b' target=_blank style='color:#2F92EE;'>#血管生成素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89704, encryptionId=93bc89e043b, topicName=血管生成素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff2526069317, createdName=xinmeili, createdTime=Sat Dec 29 02:38:00 CST 2018, time=2018-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334060, encodeId=9f1e334060bb, content=学了, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKcmgibQ4oCrK7Z6f4CvMcs4k7QUGCkhopcGxvxaBfVciadECSIwaRVttllIOEKumpEaRrq5PoOUxow/0, createdBy=e3bb2081203, createdName=哈哈869, createdTime=Wed Jul 25 12:04:04 CST 2018, time=2018-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333718, encodeId=7788333e185a, content=学了, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKcmgibQ4oCrK7Z6f4CvMcs4k7QUGCkhopcGxvxaBfVciadECSIwaRVttllIOEKumpEaRrq5PoOUxow/0, createdBy=e3bb2081203, createdName=哈哈869, createdTime=Tue Jul 24 00:12:38 CST 2018, time=2018-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417181, encodeId=7938141e181b5, content=<a href='/topic/show?id=8b72e769056' target=_blank style='color:#2F92EE;'>#组织工程#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77690, encryptionId=8b72e769056, topicName=组织工程)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c62f3243688, createdName=zhu_jun9838, createdTime=Sun Jul 22 13:38:00 CST 2018, time=2018-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419267, encodeId=22ae141926e2f, content=<a href='/topic/show?id=2e2e10182602' target=_blank style='color:#2F92EE;'>#骨缺损#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101826, encryptionId=2e2e10182602, topicName=骨缺损)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51173492599, createdName=lfcmxl, createdTime=Sun Jul 22 13:38:00 CST 2018, time=2018-07-22, status=1, ipAttribution=)]
  10. [GetPortalCommentsPageByObjectIdResponse(id=1918207, encodeId=50a4191820e2e, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Mar 14 07:38:00 CST 2019, time=2019-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787506, encodeId=29761e87506a3, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Thu Jul 04 02:38:00 CST 2019, time=2019-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996200, encodeId=62831996200e4, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon May 06 12:38:00 CST 2019, time=2019-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990152, encodeId=5c69199015260, content=<a href='/topic/show?id=e2ea89e07d9' target=_blank style='color:#2F92EE;'>#血管生成素2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89707, encryptionId=e2ea89e07d9, topicName=血管生成素2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Sat Dec 08 13:38:00 CST 2018, time=2018-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908450, encodeId=359a190845027, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sun Feb 10 06:38:00 CST 2019, time=2019-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666882, encodeId=d9c11666882f2, content=<a href='/topic/show?id=93bc89e043b' target=_blank style='color:#2F92EE;'>#血管生成素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89704, encryptionId=93bc89e043b, topicName=血管生成素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff2526069317, createdName=xinmeili, createdTime=Sat Dec 29 02:38:00 CST 2018, time=2018-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334060, encodeId=9f1e334060bb, content=学了, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKcmgibQ4oCrK7Z6f4CvMcs4k7QUGCkhopcGxvxaBfVciadECSIwaRVttllIOEKumpEaRrq5PoOUxow/0, createdBy=e3bb2081203, createdName=哈哈869, createdTime=Wed Jul 25 12:04:04 CST 2018, time=2018-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333718, encodeId=7788333e185a, content=学了, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKcmgibQ4oCrK7Z6f4CvMcs4k7QUGCkhopcGxvxaBfVciadECSIwaRVttllIOEKumpEaRrq5PoOUxow/0, createdBy=e3bb2081203, createdName=哈哈869, createdTime=Tue Jul 24 00:12:38 CST 2018, time=2018-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417181, encodeId=7938141e181b5, content=<a href='/topic/show?id=8b72e769056' target=_blank style='color:#2F92EE;'>#组织工程#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77690, encryptionId=8b72e769056, topicName=组织工程)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c62f3243688, createdName=zhu_jun9838, createdTime=Sun Jul 22 13:38:00 CST 2018, time=2018-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419267, encodeId=22ae141926e2f, content=<a href='/topic/show?id=2e2e10182602' target=_blank style='color:#2F92EE;'>#骨缺损#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101826, encryptionId=2e2e10182602, topicName=骨缺损)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51173492599, createdName=lfcmxl, createdTime=Sun Jul 22 13:38:00 CST 2018, time=2018-07-22, status=1, ipAttribution=)]
    2018-07-22 lfcmxl